Estimate of Economic Impact of Immune Checkpoint Inhibitors for NSCLC Relative to PD-L1 Expression in the US

被引：1
|
作者：
Aguiar, Pedro, Jr. [1 ]
De Mello, Ramon [2 ]
Tadokoro, Hakaru [1 ]
Babiker, Hani [3 ]
Gutierres, Barbara [4 ]
Lopes, Gilberto [5 ]
机构：
[1] Univ Fed Sao Paulo, Sao Paulo, Brazil
[2] Univ Algarve, Faro, Portugal
[3] Honor Hlth, Scottsdale, AZ USA
[4] Univ Paulista, Sao Paulo, Brazil
[5] Ctr Paulista, Oncol & Oncoclin Grp, Sao Paulo, Brazil
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
biomarker; Immunotherapy; Cost of Care; Access;
D O I：
10.1016/j.jtho.2016.11.324
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA17.01
引用
收藏
页码：S308 / S308
页数：1
相关论文
共 50 条
  • [31] Prognostic value of serum proteomic signature in NSCLC patients on immune checkpoint inhibitors: Impact of treatment regimen and PD-L1 levels
    Kim, Leeseul
    Um, Taegyu
    Chae, Young Kwang
    Cho, Allen
    CANCER RESEARCH, 2024, 84 (06)
  • [32] Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma
    Hashimoto, Kazuhiko
    Nishimura, Shunji
    Akagi, Masao
    DIAGNOSTICS, 2020, 10 (08)
  • [33] Neoadjuvant PD-1/PD-L1 Immune Checkpoint Inhibitors in Solid Tumors
    Zhao, S.
    Li, X.
    Wang, S.
    Wang, Y.
    Huang, D.
    Da, Y.
    Song, Z.
    Chen, J.
    Manegold, C.
    Peng, L.
    Xu, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S651 - S651
  • [34] Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
    Iosune Baraibar
    Ignacio Melero
    Mariano Ponz-Sarvise
    Eduardo Castanon
    Drug Safety, 2019, 42 : 281 - 294
  • [35] Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
    Baraibar, Iosune
    Melero, Ignacio
    Ponz-Sarvise, Mariano
    Castanon, Eduardo
    DRUG SAFETY, 2019, 42 (02) : 281 - 294
  • [36] Pyrazolones as inhibitors of immune checkpoint blocking the PD-1/PD-L1 interaction
    Le Biannic, Raphael
    Magnez, Romain
    Klupsch, Frederique
    Leleu-Chavain, Natascha
    Thiroux, Bryan
    Tardy, Morgane
    El Bouazzati, Hassiba
    Dezitter, Xavier
    Renault, Nicolas
    Vergoten, Gerard
    Bailly, Christian
    Quesnel, Bruno
    Thuru, Xavier
    Millet, Regis
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 236
  • [37] Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC
    Kloten, Vera
    Lampignano, Rita
    Krahn, Thomas
    Schlange, Thomas
    CELLS, 2019, 8 (08)
  • [38] An update on companion and complementary diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC
    Jorgensen, Jan Trost
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2021, 21 (05) : 445 - 454
  • [39] Immune checkpoint inhibitors' (ICI) efficacy according to PD-L1 expression for advanced or metastatic NSCLC: Systematic review and meta-analysis.
    Maciel, Glauber
    Carlos, Paula
    Murad Junior, Munir
    Araujo, Vania Eloisa
    Guerra, Augusto
    Acurcio, Francisco Assis
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] A plasma miRNA signature classifier identifies PD-L1 ≥ 50% NSCLC nonresponders to immune checkpoint inhibitors.
    Proto, Claudia
    Prelaj, Arsela
    Verri, Carla
    Signorelli, Diego
    Lo Russo, Giuseppe
    Ferrara, Roberto
    Galli, Giulia
    Trevisan, Benedetta
    Mavis, Mensah
    De Braud, Filippo G.
    Garassino, Marina Chiara
    Sozzi, Gabriella
    Boeri, Mattia
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345